Hi1a is still hard science—but it just got easier to make

The stories we tell about peptide therapeutics usually start with biology: a receptor, an ion channel, a pathway that looks like a lever on disease.

But many peptide programs don’t die because the biology was wrong. They stall because the molecule is too annoying to make.

Hi1a—an intricate, disulfide‑rich venom peptide first isolated from the Australian funnel‑web spider Hadronyche infensa—has lived in that uncomfortable space for years. It’s been studied as a neuroprotective candidate in models of ischemic injury via inhibition of acid‑sensing ion channel 1a (ASIC1a). The idea is compelling enough that the peptide keeps showing up in “what if” conversations about stroke. The practical problem is that Hi1a is 76 amino acids long and folds into a complex structure that’s easy to admire and hard to manufacture.

A new chemistry paper doesn’t answer the clinical “does it work?” question. Instead, it answers a different question—one that quietly controls how fast the rest of the science moves: Can we make the stuff quickly enough to iterate?

In the Journal of Organic Chemistry, Byrne and colleagues report “Rapid Chemical Synthesis of Neuroprotective Hi1a”, describing what they call the first “single-shot” chemical synthesis of Hi1a using automated fast‑flow peptide synthesis (AFPS).

The bottleneck was never just folding—it was access

When a peptide is rare, every experiment becomes precious. Labs ration material, avoid exploring analogs, and spend as much time planning around supply as they do interpreting results. That’s especially true for venom peptides, where recombinant expression may not be straightforward and chemical synthesis can become a project in its own right.

In their abstract, the authors describe synthesizing linear Hi1a (not the final folded, disulfide‑connected form) in under 4.5 hours total synthesis time, producing more than 10 milligrams.

If you’re not used to peptide manufacturing, that number can sound tiny. For a drug product, it is tiny. For a research program, it’s often the difference between “one careful set of experiments” and “a real cycle of design, synthesis, and testing.”

Why “linear” matters—and why this still counts

Hi1a’s biological activity depends on folding and correct disulfide connectivity. Producing linear peptide quickly doesn’t automatically solve folding, purification, and reproducibility challenges. It also doesn’t guarantee that other labs, with other AFPS setups, will get the same yields.

So it’s fair to be skeptical.

But it’s also fair to notice what the paper changes. If you can reliably generate linear material fast, you can spend your scarce time optimizing the step that actually determines function: folding and oxidation conditions, disulfide mapping, and—eventually—engineering analogs that keep the pharmacology while being less finicky.

A useful comparison: what “hard to make” looked like before

This isn’t the first time chemists have gone after Hi1a. A prior paper—“Total Synthesis of the Spider‑Venom Peptide Hi1a”—described total synthesis using native chemical ligation, with successful folding and activity comparable to recombinant Hi1a.

That older work is an important reminder: Hi1a can be made and folded by chemical methods, but historically it has not been fast or convenient. The new AFPS approach is best seen as an attempt to turn Hi1a from a boutique molecule into something more labs can access.

Why this kind of progress matters for patients, indirectly

It’s tempting to dismiss manufacturing advances as “inside baseball.” Patients don’t get healthier because a synthesis run is shorter.

But manufacturing is the gatekeeper to everything that comes next: reproducible biology, medicinal chemistry iteration, toxicology prep, and the early work that tells you whether a molecule is worth the expensive leap into human studies.

If Hi1a or Hi1a‑like analogs ever become real therapies, it will be because the field learned how to make, fold, and validate them as reliably as it learned their mechanism.

For now, this paper is a small but meaningful shift in momentum: it makes it easier to do the experiments that will determine whether Hi1a remains a fascinating venom peptide—or becomes a platform for something clinically useful.

The bottleneck was never just folding—it was access

Why “linear” matters—and why this still counts

A useful comparison: what “hard to make” looked like before

Why this kind of progress matters for patients, indirectly

Further reading

Related reading